Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
NCT04837040 · Crinetics Pharmaceuticals Inc. · PHASE3 · terminated · last registry update 2026-07-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine).” | – | Registry record, Crinetics Pharmaceuticals Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SSTR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Phase 3 first posted: Tata Memorial Hospital, Capecitabine + Temozolomide (TMZ) (NCT07910760)
- 2026-10-29Also stopped (suspended): Azienda Ospedaliero Universitaria Maggiore della Carita, a drug against SSTR2 (NCT05298891)
- 2026-10-13Also stopped (withdrawn): University of Alabama at Birmingham, Octreotide (drug) + Placebo (NCT06881888)
- 2026-09-25Phase 3 first posted: Washington University School of Medicine, Somatostatin Analogue(s) (NCT07842172)
- 2026-09-03Also stopped (terminated): AHS Cancer Control Alberta, [68]Ga-HA-DOTATATE (NCT03145857)
- 2026-08-31Also stopped (withdrawn): Weill Medical College of Cornell University, Ga-68- DOTATATE + Ga-68-DOTATOC (NCT04298541)
- 2026-08-28Results posted on the registry: Nicholas Fidelman, MD, Pembrolizumab + Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (NCT03457948)
- 2026-08-20Results posted on the registry: Camurus AB, CAM2029 (octreotide subcutaneous depot) + Matching placebo (NCT04076462)
- 2026-08-07Also stopped (terminated): Alexion Pharmaceuticals, Inc., ALXN2420 + Placebo (NCT07037420)
- 2026-07-29Also stopped (terminated): Crinetics Pharmaceuticals Inc., Paltusotine (NCT04261712)
- 2026-07-27Also stopped (suspended): AHS Cancer Control Alberta, [177]Lu-DOTA-TATE (NCT01876771)
- 2026-07-15Also stopped (terminated): Crinetics Pharmaceuticals Inc., Paltusotine + Placebo (NCT05192382)
- 2026-06-03Phase 3 first posted: CSPC ZhongQi Pharmaceutical Technology Co., Ltd., SYHX2008 + Sandostatin LAR® (NCT07623824)
- 2026-06-01Results posted on the registry: Camurus AB, CAM2029 + Placebo (NCT05281328)
- 2026-05-22Also stopped (suspended): National Cancer Centre, Singapore, a drug against SSTR2 (NCT05198479)
- 2026-04-28Results posted on the registry: Grupo Espanol de Tumores Neuroendocrinos, Axitinib + Sandostatin LAR (NCT01744249)
- 2026-04-06Results posted on the registry: ITM Solucin GmbH, 177Lu-edotreotide PRRT + Everolimus (NCT03049189)
- 2026-04-03Also stopped (suspended): Mayo Clinic, Somatostatin analog (NCT04329039)
- 2026-03-18Phase 3 first posted: Shanghai Zhongshan Hospital, Octreotide Microspheres + Placebo (NCT07479784)
- 2026-02-05Also stopped (terminated): Ariceum Therapeutics GmbH, 225Ac-SSO110 + SoC + Atezolizumab (NCT06939036)
- 2026-01-21Results posted on the registry: National Cancer Institute (NCI), Sacituzumab Govitecan + Loperamide (NCT06865677)
- 2026-01-21Also stopped (terminated): National Cancer Institute (NCI), Sacituzumab Govitecan + Loperamide (NCT06865677)
- 2026-01-14Also stopped (terminated): Imperial College London, Lutathera (NCT05987176)
- 2026-01-13Results posted on the registry: Crinetics Pharmaceuticals Inc., Paltusotine + Placebo (NCT05192382)
- 2025-11-20Results posted on the registry: Medical University of South Carolina, Octreotide (NCT03624517)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision